Clinical Trials
109 trialsLisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
The Affiliated People's Hospital of Ningbo University
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
TUD-APOLLO-064
Technische Universität Dresden
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
Eastern Cooperative Oncology Group
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
QUATRO-APL
Quetzal Therapeutics
LATITUDE
SDK Therapeutics, Inc.
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
SDK Therapeutics, Inc.
LEAP
Harvard Medical School (HMS and HSDM)
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Frontline Oral Arsenic Trioxide for APL
The University of Hong Kong
IC-APL2020
Instituto do Cancer do Estado de São Paulo
Ven APL
The First Affiliated Hospital of Soochow University
Optimum Induction Therapy of Low-risk APL
Peking University People's Hospital
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
SWOG Cancer Research Network
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
APL16
First Affiliated Hospital Xi'an Jiaotong University
"AIDA" Protocol (LAP 0493)
Gruppo Italiano Malattie EMatologiche dell'Adulto
AIDA 2000 Guidelines
Gruppo Italiano Malattie EMatologiche dell'Adulto
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
RIF
Peking University People's Hospital
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Orsenix LLC
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Red Cell Transfusion Goals in Patients With Acute Leukemias
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Wake Forest University Health Sciences
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Washington
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
A Safety Study of SGN-CD33A in AML Patients
Seagen Inc.
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center